Hedge Fund Adds Jazz Drug To List Of AIA Review Targets
An organization tied to hedge fund manager Kyle Bass on Monday asked the Patent Trial and Appeal Board to invalidate a patent covering Jazz Pharmaceuticals Inc.'s narcolepsy drug Xyrem, the latest...To view the full article, register now.
Already a subscriber? Click here to view full article